Form 8-K - Current report:
SEC Accession No. 0001641172-25-011387
Filing Date
2025-05-19
Accepted
2025-05-19 08:19:09
Documents
25
Period of Report
2025-05-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 102318
2 EX-2.1 ex2-1.htm EX-2.1 695282
3 EX-3.1 ex3-1.htm EX-3.1 93058
4 EX-3.2 ex3-2.htm EX-3.2 102488
5 EX-3.3 ex3-3.htm EX-3.3 300708
6 EX-4.1 ex4-1.htm EX-4.1 162941
7 EX-10.1 ex10-1.htm EX-10.1 161217
8 EX-10.2 ex10-2.htm EX-10.2 115552
9 EX-10.3 ex10-3.htm EX-10.3 48097
10 EX-10.4 ex10-4.htm EX-10.4 99153
11 EX-99.1 ex99-1.htm EX-99.1 26568
12 GRAPHIC ex99-1_001.jpg GRAPHIC 22258
13 GRAPHIC ex99-1_002.jpg GRAPHIC 10886
  Complete submission text file 0001641172-25-011387.txt   2532588

Data Files

Seq Description Document Type Size
14 XBRL SCHEMA FILE ptix-20250515.xsd EX-101.SCH 3515
15 XBRL DEFINITION FILE ptix-20250515_def.xml EX-101.DEF 26546
16 XBRL LABEL FILE ptix-20250515_lab.xml EX-101.LAB 36500
17 XBRL PRESENTATION FILE ptix-20250515_pre.xml EX-101.PRE 25170
27 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5561
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 25961566
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)